NSEPress Release15 Jul 2026 · 15 Jul 2026, 08:40 am
Press Release
Sun Pharmaceutical Industries Limited · SUNPHARMA
✦ AI Summary▲ PositiveOrder Win
Sun Pharmaceutical Industries Limited has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus.
Analysis Scores
Earnings Impact2/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 15, 2026, titled "Sun Pharma receives approval to manufacture and market generic semaglutide in South Africa".
Attachments (1)
📄pdf
Download →
SUNPHARMA123_15072026083753_SEIntimationPRSemaglutidesigned.pdf
View document text
Sun Pharmaceutical Industries Limited
SUN HOUSE, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050
15 July 2026
National Stock Exchange of India Limited BSE Limited
Scrip Symbol: SUNPHARMA Scrip Code: 524715
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 – Press Release
Enclosed herewith is a copy of the press release titled “Sun Pharma receives approval to manufacture
and market generic semaglutide in South Africa,” which shall be released after this intimation.
For Sun Pharmaceutical Industries Limited
(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983
Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA
Reaching People. Touching Lives
Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050
FOR IMMEDIATE RELEASE
Sun Pharma receives approval to manufacture and market
generic semaglutide in South Africa
Mumbai, India, July 15, 2026 - Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg:
SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or
associate companies) announced that it has received approval from the South African Health Products
Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection
in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an
adjunct to diet and exercise.
Sun Pharma plans to launch the product in the market in the coming days. It will be available as a
pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) that allow flexible,
once-weekly dosing.
“South Africa is the second market after India where Sun Pharma has received approval for generic
semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent
quality standards across different markets. We remain committed to improving access to generics and
making evidence-based treatment options available to patients and healthcare professionals," said Aalok
Shanghvi, Chief Operating Officer, Sun Pharma.
South Africa faces a growing burden of type 2 diabetes, driven in part by rapid urbanization and
changing lifestyles. This rising prevalence places significant pressure on patients and healthcare
services. Improving access to effective therapies is therefore an important component of addressing
this national health challenge.
About Sun Pharmaceutical Industries Limited. (CIN - L24230GJ1993PLC019050)
Sun Pharma is a leading global pharmaceutical company with a presence in Innovative Medicines, Generics and
Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company
in the US as well as Global Emerging Markets. Sun’s high growth Global Innovative Medicines portfolio spans
innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 22% of
company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by
physicians and consumers in over 100 countries. Its manufacturing facilities are spread across five continents. Sun
Pharma is proud of its multi-cultural workforce drawn from over 50 nations. “For further information, please visit
www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter).”
Contacts:
Investors Media
Dr. Abhishek Sharma Gaurav Chugh
Tel +91 22 4324 4324, Xtn 2929 Tel +91 22 4324 4324, Xtn 5373
Tel (D) +91 22 4324 2929 Tel (D) +91 22 4324 5373
Mobile +91 98196 86016 Mobile +91 98104 71414
E mail abhi.sharma@sunpharma.com E mail gaurav.chugh@sunpharma.com
Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.
Reaching People. Touching Lives.